Literature DB >> 2646129

On-off phenomenon in a child with tetrahydrobiopterin deficiency due to 6-pyruvoyl tetrahydropterin synthase deficiency (BH4 deficiency).

Y Tanaka1, N Matsuo, S Tsuzaki, K Araki, Y Tsuchiya, A Niederwieser.   

Abstract

Marked fluctuations in mobility, known as the on-off phenomenon, frequently emerge during the course of chronic treatment with levodopa in patients with Parkinson's disease. Similar fluctuations in mobility and mental status have been observed in a 10-year-old Japanese girl with tetrahydrobiopterin deficiency (BH4 deficiency) while receiving neurotransmitter and biopterin supplement. In order to define the underlying mechanisms for the phenomenon in our patient, we studied the temporal relationship between plasma levodopa levels and clinical status during oral (2.0 mg/kg per day) and continuous intravenous (2.0 mg/kg per 12 h) administration of the drug. Following each oral levodopa dose, the plasma concentration of levodopa peaked at 60-90 ng/ml within 60 min and fell to 5-15 ng/ml within 2 h. The clinical state of the patient varied acutely in parallel with the plasma levodopa concentrations. The clinical swings completely disappeared when the plasma levodopa concentrations were stabilized between 120-150 ng/ml by continuous infusion. Paradoxically, on awakening from sleep, she was invariably ambulatory despite very low plasma levodopa levels (less than 10 ng/ml). These observations indicate that the on-off phenomenon in our patient reflect the fluctuations of plasma levodopa levels as demonstrated in Parkinson's disease, but there may be substantial differences in levodopa transport across the blood-brain barrier and/or striatal dopamine-receptor interaction between Parkinson's disease and BH4 deficiency.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2646129     DOI: 10.1007/bf00595911

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  5 in total

1.  Fluctuation in response to chronic levodopa therapy: pathogenetic and therapeutic considerations.

Authors:  T N Chase; J Juncos; C Serrati; G Fabbrini; G Bruno
Journal:  Adv Neurol       Date:  1987

2.  Plasma dopa concentrations and the "on-off" effect after chronic treatment of Parkinson's disease.

Authors:  R D Sweet; F H McDowell
Journal:  Neurology       Date:  1974-10       Impact factor: 9.910

3.  Pharmacokinetics of levodopa and motor fluctuations.

Authors:  R J Hardie; A J Lees; G M Stern
Journal:  Adv Neurol       Date:  1987

4.  Biochemical pathophysiology of Parkinson's disease.

Authors:  O Hornykiewicz; S J Kish
Journal:  Adv Neurol       Date:  1987

5.  Analysis of cysteinyldopas, dopa, dopamine, noradrenaline and adrenaline in serum and urine using high-performance liquid chromatography and electrochemical detection.

Authors:  C Hansson; G Agrup; H Rorsman; A M Rosengren; E Rosengren; L E Edholm
Journal:  J Chromatogr       Date:  1979-01-01
  5 in total
  3 in total

1.  Monitoring treatment in tetrahydrobiopterin deficiency by serum prolactin.

Authors:  M Spada; S Ferraris; G B Ferrero; M Sartore; C Lanza; F Perfetto; L de Sanctis; C Dompé; N Blau; A Ponzone
Journal:  J Inherit Metab Dis       Date:  1996       Impact factor: 4.982

2.  Monoamine oxidase inhibitors in tetrahydrobiopterin deficiency.

Authors:  A Schuler; N Blau; A Ponzone
Journal:  Eur J Pediatr       Date:  1995-12       Impact factor: 3.183

3.  Genetic and pharmacological correction of aberrant dopamine synthesis using patient iPSCs with BH4 metabolism disorders.

Authors:  Taizo Ishikawa; Keiko Imamura; Takayuki Kondo; Yasushi Koshiba; Satoshi Hara; Hiroshi Ichinose; Mahoko Furujo; Masako Kinoshita; Tomoko Oeda; Jun Takahashi; Ryosuke Takahashi; Haruhisa Inoue
Journal:  Hum Mol Genet       Date:  2016-12-01       Impact factor: 6.150

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.